Shanghai ERP Biotechnology: difference between revisions
Diff·revision 18 → 19·02:08, 24 Aug 2025
Difference between revision 18 and revision 19 of Shanghai ERP Biotechnology. 5 lines changed; the page grew by 762 bytes.
| Revision 18 — 23:03, 19 Aug 2025 COA_Colwyn (talk) split section 4,147 bytes ±0 | Revision 19 — 02:08, 24 Aug 2025 ArchiveBot (talk) bot: normalise citation format 4,909 bytes +762 | ||
|---|---|---|---|
| 27 | The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report. | 27 | The organisation distributes through six regional warehouses rather than shipping every order from the manufacturing site: Netherlands (Rotterdam), serving European Union, typically 2-4 days; Germany (Hamburg), serving Germany, Austria, Switzerland, typically 2-4 days; United Kingdom (London), serving United Kingdom & Ireland, typically 2-3 days; United States (California), serving United States, typically 2-4 days; Canada (Toronto), serving Canada, typically 3-5 days; Australia (Melbourne), serving Australia & New Zealand, typically 3-5 days. Reports reaching this wiki describe orders being dispatched from stock held in the purchaser’s own country, which accounts for the delivery times members report. |
| 28 | 28 | ||
| + | 29 | == Operations and documentation practice == | |
| + | 30 | Purchaser reports describe conventional practice: lyophilised material in crimped vials, batch certificate with purity and appearance, insulated packaging on the incretin lines.{{r|reports}} Water figures have appeared on a minority of the submitted certificates.{{r|usp1503}} | |
| + | 31 | ||
| 29 | == References == | 32 | == References == |
| 30 | {{reflist}} | 33 | {{reflist}} |
| 31 | <ref name="registry">National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.</ref> | 34 | <ref name="registry">National Enterprise Credit Information Publicity System (国家企业信用信息公示系统), company registration record, retrieved 2026. Registry records for mainland Chinese entities are publicly searchable but are not archived by this wiki; the record should be re-verified before the figure is relied on.</ref> |
| 32 | <ref name="selfpub">Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per [[Project:Verifiability]].</ref> | 35 | <ref name="selfpub">Organisation's own published product and company documentation, retrieved 2026. Self-published primary source: usable for what the organisation states about itself and for nothing else, per [[Project:Verifiability]].</ref> |
| + | 36 | <ref name="reports">Independent test reports submitted to PeptidePedia by purchasers, 2024–2026. Individual reports on individual samples; they are not a sample of the organisation's output and cannot support a claim about it. See [[Blind sampling]].</ref> | |
| 33 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> | 37 | <ref name="tally">PeptidePedia reception tally (self-reported submissions; '''weak evidence''' — see [[Project:Sourcing guidelines]]). Self-selected sample; period and count stated at each point of use.</ref> |
| + | 38 | <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, "Quality Attributes of Synthetic Peptide Drug Substances" (informational). USP–NF, current revision.</ref> | |
| 34 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 39 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 35 | 40 |